183 related articles for article (PubMed ID: 7560168)
1. OV 632 and MOC 31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin fixed and paraffin wax embedded material.
Edwards C; Oates J
J Clin Pathol; 1995 Jul; 48(7):626-30. PubMed ID: 7560168
[TBL] [Abstract][Full Text] [Related]
2. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
3. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.
Morgan RL; De Young BR; McGaughy VR; Niemann TH
Cancer; 1999 Dec; 87(6):390-4. PubMed ID: 10603193
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of N-cadherin in pleural mesotheliomas and E-cadherin in lung adenocarcinomas in formalin-fixed, paraffin-embedded tissues.
Han AC; Peralta-Soler A; Knudsen KA; Wheelock MJ; Johnson KR; Salazar H
Hum Pathol; 1997 Jun; 28(6):641-5. PubMed ID: 9190996
[TBL] [Abstract][Full Text] [Related]
5. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma.
Ordóñez NG
Hum Pathol; 1998 Feb; 29(2):166-9. PubMed ID: 9490276
[TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
7. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies.
Abutaily AS; Addis BJ; Roche WR
J Clin Pathol; 2002 Sep; 55(9):662-8. PubMed ID: 12194995
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.
Moch H; Oberholzer M; Dalquen P; Wegmann W; Gudat F
Virchows Arch A Pathol Anat Histopathol; 1993; 423(1):19-27. PubMed ID: 8212530
[TBL] [Abstract][Full Text] [Related]
10. Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Lyons-Boudreaux V; Mody DR; Zhai J; Coffey D
Arch Pathol Lab Med; 2008 Jan; 132(1):23-8. PubMed ID: 18181669
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma.
Leers MP; Aarts MM; Theunissen PH
Histopathology; 1998 Mar; 32(3):209-16. PubMed ID: 9568505
[TBL] [Abstract][Full Text] [Related]
12. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
Mayall FG; Goddard H; Gibbs AR
J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
[TBL] [Abstract][Full Text] [Related]
13. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
14. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma.
Clover J; Oates J; Edwards C
Histopathology; 1997 Aug; 31(2):140-3. PubMed ID: 9279564
[TBL] [Abstract][Full Text] [Related]
15. Distinguishing malignant mesothelioma from pulmonary adenocarcinoma: an immuno-histochemical approach using a panel of monoclonal antibodies.
Tuttle SE; Lucas JG; Bucci DM; Schlom J; Primus J
J Surg Oncol; 1990 Oct; 45(2):72-8. PubMed ID: 2214794
[TBL] [Abstract][Full Text] [Related]
16. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
17. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions.
Delahaye M; van der Ham F; van der Kwast TH
Diagn Cytopathol; 1997 Aug; 17(2):115-20. PubMed ID: 9258618
[TBL] [Abstract][Full Text] [Related]
18. Anti-MOC-31: a potential addition to the pulmonary adenocarcinoma versus mesothelioma immunohistochemistry panel.
Sosolik RC; McGaughy VR; De Young BR
Mod Pathol; 1997 Jul; 10(7):716-9. PubMed ID: 9237183
[TBL] [Abstract][Full Text] [Related]
19. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
20. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]